However, a newer formulation of itraconazole with increased bioavailability, SUBA-itraconazole®, was evaluated in a retrospective cohort study of 19 children (16 with CF and ABPA), where 59% achieved therapeutic level, 81% demonstrated a decline in total IgE, and it was well tolerated (Table 3) [191]. This evidence concerns the gene IGHE and cystic fibrosis.